Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

Please find enclosed a press release titled "Dr.

Reddy's Laboratories announces the launch of

Regadenoson Injection 0.4 mg/5 mL in the U.S."

This is for your information.

For Dr. Reddy's Laboratories Limited

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Dr. Reddy's Laboratories announces the launch of

Regadenoson Injection 0.4 mg/5 mL in the U.S.

Hyderabad India; May 5, 2023 - Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr.

Reddy's"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan

(Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).

Dr. Reddy's Regadenoson Injection is supplied

as single-dose pre-filled syringes, 0.4 mg/5 mL (0.08 mg/mL).

Please click here to see the full prescribing information:

Lexiscan is a registered trademark of Astellas

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,

India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good

Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars

and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep

science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter

of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high

in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements

of future expectations and other forward-looking statements that are based on the management's current views and assumptions and

involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those

expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",

"will", "should", "expects", "plans", "intends", "anticipates", "believes",

"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking

statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general

economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels

and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition

and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the

impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets

addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics

or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings

with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"

sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information